ANIP
insider transactionsANI PHARMACEUTICALS INC — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-79.0K
0 buy · 79.0K sell
Net value · 90d
-$6.2M
$0 in · $6.2M out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
10
0 buy · 79.0K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
SR. VP, GENERAL COUNSEL & SEC. · 10b5-1
$41.0K
500 sh · $82.03
Own -1%
-
Sell·S
Director · 10b5-1
$161.8K
2.0K sh · $80.88
Own -5%
-
Exercise·M
Stephen P. Carey KEY
SVP & CFO · 10b5-1
$164.0K
3.3K sh · $49.51
Own +100%
-
Sell·S
Stephen P. Carey KEY
SVP & CFO · 10b5-1
$265.0K
3.3K sh · $80.00
Own -2%
-
Exercise·M
Stephen P. Carey KEY
SVP & CFO · 10b5-1
$164.0K
3.3K sh · $49.51
Own +2%
-
Grant·A
Director
$0
4.4K sh
Own +19%
-
Grant·A
Director
$0
4.4K sh
Own +63%
-
Grant·A
Director
$0
4.4K sh
Own +19%
-
Grant·A
Director
$0
4.4K sh
Own +17%
-
Grant·A
Director · 10b5-1
$0
4.4K sh
Own +12%
-
Sell·S
SR. VP, GENERAL COUNSEL & SEC. · 10b5-1
$39.1K
500 sh · $78.16
Own -1%
-
Sell·S
Director
$806.3K
10.0K sh · $80.63
Own -21%
-
Sell·S
SVP, GENERICS
$220.4K
2.8K sh · $79.50
Own -3%
-
Sell·S
SVP, HEAD - ESTABLISHED BRANDS
$36.4K
459 sh · $79.21
Own -1%
-
Sell·S
Nikhil Lalwani KEY
PRESIDENT & CEO
$4.3M
55.0K sh · $77.57
Own -14%
-
Sell·S
Director
$320.8K
4.0K sh · $80.75
Own -8%
-
Sell·S
SR. VP, GENERAL COUNSEL & SEC. · 10b5-1
$39.0K
500 sh · $77.95
Own -1%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 12, 2026 | Meredith Cook 10b5-1 | Sell S | 500 | $41.0K |
| Jun 8, 2026 | Thomas Haughey 10b5-1 | Sell S | 2.0K | $161.8K |
| Jun 5, 2026 | Stephen P. Carey KEY 10b5-1 | Exercise M | 3.3K | $164.0K |
| Jun 5, 2026 | Stephen P. Carey KEY 10b5-1 | Sell S | 3.3K | $265.0K |
| Jun 5, 2026 | Stephen P. Carey KEY 10b5-1 | Exercise M | 3.3K | $164.0K |
| May 21, 2026 | Jeanne Thoma | Grant A | 4.4K | $0 |
| May 21, 2026 | Matthew J Leonard | Grant A | 4.4K | $0 |
| May 21, 2026 | Antonio R Pera | Grant A | 4.4K | $0 |
| May 21, 2026 | Renee P Tannenbaum | Grant A | 4.4K | $0 |
| May 21, 2026 | Thomas Haughey 10b5-1 | Grant A | 4.4K | $0 |
| May 13, 2026 | Meredith Cook 10b5-1 | Sell S | 500 | $39.1K |
| May 13, 2026 | Patrick D Walsh | Sell S | 10.0K | $806.3K |
| May 12, 2026 | Ori Gutwerg | Sell S | 2.8K | $220.4K |
| May 12, 2026 | Thomas Andrew Rowland | Sell S | 459 | $36.4K |
| May 11, 2026 | Nikhil Lalwani KEY | Sell S | 55.0K | $4.3M |
| May 11, 2026 | Patrick D Walsh | Sell S | 4.0K | $320.8K |
| Apr 13, 2026 | Meredith Cook 10b5-1 | Sell S | 500 | $39.0K |
About ANIP insider trading
This page tracks insider transactions for ANI PHARMACEUTICALS INC (ANIP) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.